- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01229280
Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.
Comparative Bioavailability of Darifenacin Extended Release Oral Formulation [Darisec(R)7.5 mg vs. Enablex(R)7.5 mg]: Single-dose, Postprandial State, Randomized, Two-sequence, Two-period, Crossover Study in Healthy Volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Darifenacin is a muscarinic receptor antagonist drug used to treat overactive bladder. There is a new formulation of darifenacin extended release developed by an argentinian pharmaceutical company. A bioequivalence study will be performed to validate pharmaceutical development before introducing the product in the market.
The purpose in this study is to evaluate the relative bioavailability, pharmacokinetic profiling and safety of a brand generic formulation of darifenacin [Darisec(R) 7.5 mg] vs. the innovator [Enablex(R) 7.5 mg]in 24 healthy uruguayan volunteers after a high fat breakfast of 1000 calories (50% fat, 35% carbohydrates, and 15% proteins)to establish their average bioequivalence.
The bioequivalence will be evaluated using:
- The Area Under the Curve (AUC),
- The peak plasma concentration (Cmax).
The pharmacokinetic characteristics of the drug formulations will be described calculating:
- The time to peak concentration (Tmax)
- The elimination constant (Ke)
- The elimination half-life (t1/2e)
- The systemic clearance (Cls)
Safety will be evaluated recording:
- Reported adverse events
- Vital signs (blood pressure, heart rate, body temperature)
- Laboratory analysis (hemogram, hepatic enzymes, creatinine, sugar in blood, etc.)
- EKG and chest XRays
Bioequivalence will be claimed if the drugs comply with local and FDA regulatory requirements:
- Mean AUCt/AUCr and 90% confidence interval within 0.80-1.25
- Mean Cmaxt/Cmaxr and 90% confidence interval within 0.80-1.25
Pharmacokinetic profiling will be evaluated by describing the pharmacokinetic characteristics of both drug in adequate two-way tables.
Safety will be evaluated comparing incidence of adverse events/adverse effects for both products.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Federico Santoro, MD
- Phone Number: +541143794300
- Email: santorof@elea.com
Study Contact Backup
- Name: Joanna Steimberg, MBA
- Phone Number: +541143794330
- Email: steimbej@elea.com
Study Locations
-
-
-
Montevideo, Uruguay, 11600
- Center for Clinical Pharmacology Research (CCPR) Bdbeq S.A. Hospital Italiano.
-
Contact:
- Francisco E. Estevez-Carrizo, M.D.
- Phone Number: +59824876288
- Email: francisco.estevez@bdbeq.com.uy
-
Contact:
- Mónica Cedrés, Pharm. B.
- Phone Number: +59824876288
- Email: mcderes@bdbeq.com.uy
-
Principal Investigator:
- Susana Parrillo, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female subjects 18 to 50 years of age (inclusive).
- In good health, as determined by lack of clinically significant abnormalities at screening as judged by the physician.
- Female subjects are required to use a medically accepted method of hormonal contraception or abstinence throughout the entire study period and for one week after the study is completed.
- Body mass index within the range of 18.5 and 29.9 kg/m2 and weight at least 45 kg.
Exclusion Criteria:
- Known hypersensitivity or severe adverse event to darifenacin or similar drugs.
- Urinary, retention, narrow-angle glaucoma, myasthenia gravis, severe hepatic impairment, severe ulcerative colitis, toxic megacolon.
- Symptomatic hiatus hernia, erosive or symptomatic gastroesophageal reflux disease/heartburn (>2 days in a week), severe constipation, gastrointestinal obstructive disorder, and gastric retention.
- Clinically significant cardiac abnormalities, fainting, low blood pressure upon standing, irregular heartbeats.
- Acute or chronic bronchospastic disease(including asthma and Chronic Obstructive Pulmonary Disease).
- Clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis).
- Smokers of more than 5 cigarettes a week.
- Regular use of any drug known to induce or inhibit hepatic drug metabolism (particularly those that affect CYP2D6) within 30 days prior to each study drug administration.
- Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs which may jeopardize participation in the study.
- Immunodeficiency diseases, including a positive HIV (Elisa or Western blot) test result.
- Positive Hepatitis B Surface antigen (HBsAg) or Hepatitis C results.
- Drug or alcohol abuse within the 6 months prior to dosing.
- Use of prescription drugs within 1 month prior to dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements)within 2 weeks prior to dosing. Paracetamol and ibuprofen are acceptable.
- Participation in any clinical investigation within 12 weeks prior to dosing.
- Donation or loss of 400 ml or more of blood within 8 weeks prior to dosing.
- Significant illness within 2 weeks prior to dosing.
- Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Darisec(R) 7.5 mg
|
Single dose 7.5 mg tablets of darifenacin
Other Names:
Single dose 7.5 mg tablets of Darifenacin
Other Names:
|
Active Comparator: Enablex(R) 7.5 mg
|
Single dose 7.5 mg tablets of darifenacin
Other Names:
Single dose 7.5 mg tablets of Darifenacin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Extent of absorption
Time Frame: 72 hours
|
Extent of absorption will be measured using the area under the plasma concentration of darifenacin vs time from time 0 to the last sample point (AUC0-t) and from time 0 to infinity (AUC0-inf.
|
72 hours
|
Rate of absorption
Time Frame: 72
|
Rate of abosorption will be measured using peak concentration of darifenacin (Cmax)taken from the concentration vs. time curve.
|
72
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to peak concentration (tmax)
Time Frame: 72
|
Tmax is the time elapsed from ingestion of darifenacin tablets to plasma peak concentration (Cmax)
|
72
|
Elimination rate constant (Ke)
Time Frame: 72 hours
|
The elimination rate constant is the fractional rate of drug disappearance form the peripheral compartement, measured in the log-linear elimination phase.
|
72 hours
|
Elimination Half-life (t1/2e)
Time Frame: 72 hours
|
t1/2e is the time in which the concentration in the log-linear elimination phase drops by half.
|
72 hours
|
Systemic clearance (Cls)
Time Frame: 72 hours
|
Cls is the amount of plasma volume units that are totally cleared of the drug in the unit of time.
|
72 hours
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Francisco E. Estevez-Carrizo, MD, Univerisity of Montevideo. Biomedical Science Center.Prudencio de Pena 2440, 11600 Montevideo. Uruguay
- Principal Investigator: Susana Parrillo, M.D., Center for Clinical Pharmacology Research Bdbeq S.A., Br. Artigas 1632. c.p. 11600 Montevideo. Uruguay.
Publications and helpful links
General Publications
- Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. doi: 10.2165/00003088-200645040-00001.
- Croom KF, Keating GM. Darifenacin: in the treatment of overactive bladder. Drugs Aging. 2004;21(13):885-92; discussion 893-4. doi: 10.2165/00002512-200421130-00005.
- Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22(12):1013-28. doi: 10.2165/00002512-200522120-00003.
- Kerbusch T, Wahlby U, Milligan PA, Karlsson MO. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol. 2003 Dec;56(6):639-52. doi: 10.1046/j.1365-2125.2003.01967.x.
- Dmochowski RR, Appell RA. Advancements in pharmacologic management of the overactive bladder. Urology. 2000 Dec 4;56(6 Suppl 1):41-9. doi: 10.1016/s0090-4295(00)01020-7.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BDBEQ_DFNLP/ELEA_010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioequivalency
-
Center for Clinical Pharmacology Research Bdbeq...Laboratorio Elea Phoenix S.A.Unknown
-
Perrigo CompanyCompleted
-
Perrigo CompanyCompleted
-
Kremers Urban Development CompanyWatson Laboratories, Inc.Completed
-
Perrigo CompanyCompleted
-
Perrigo CompanyCompleted
-
Xcovery Holdings, Inc.CompletedBioequivalencyUnited States
Clinical Trials on Darifenacin
-
NovartisProcter and GambleCompleted
-
BayerCompleted
-
BayerTerminatedMultiple Sclerosis | Overactive DetrusorGermany
-
Cognitive Research CorporationNovartis PharmaceuticalsWithdrawn
-
BayerCompletedOveractive BladderSouth Africa
-
McGill UniversityUniversité de MontréalNot yet recruitingAmyotrophic Lateral SclerosisCanada
-
US Department of Veterans AffairsCompletedOveractive Bladder | Parkinson's DiseaseUnited States
-
Toronto Rehabilitation InstituteOntario Neurotrauma FoundationCompletedSpinal Cord Injury | Neurogenic Detrusor OveractivityCanada
-
NovartisCompletedOveractive Bladder SyndromeUnited States
-
University of Missouri-ColumbiaTerminatedOveractive Bladder | Renal Colic | Pain, PostoperativeUnited States